Aim immunotech announces the expansion of its pancreatic cancer program to include new patients in the netherlands

Early access program will also allow further treatment of patients treated under the previous ampligen early access program early access program will also allow further treatment of patients treated under the previous ampligen early access program
AIM Ratings Summary
AIM Quant Ranking